Abstract
Behçet’s syndrome (BS) is a systemic vasculitis of unknown etiology. There are several reasons for doubting a primary autoimmune pathogenesis of this condition. Recent information suggests evidence for genetic anticipation. Although there is heightened inflammatory activity, as exemplified by the pathergy reaction, wound healing in BS is normal. BS also runs a more stormy course in adults and in the young. However, the amount of androgen receptors in scrotal skin have not found to be increased. Another unsolved problem is the nature of acnelike lesions and how they differ from acne vulgaris (AV). Only lesions in “non-acne” areas were compared between the two conditions, and no differences were detected. Mortality is increased in BS, especially among males. Azathioprine proved to be effective in disease control after 8 years of follow-up. We have also recently finished a 24 week controlled trial of two doses of thalidomide, 100 mg and 300 mg per day. Both doses were superior to placebo, with no real differences in efficacy, in controlling the oral and genital ulcers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Yurdakul S, Gunaydin I, Tuzun Y, Ozyazgan O, Pazarli H, Yazici H. The prevalence of Behçet’s syndrome in a rural area in Turkey. J. Rheumatol 15: 882–890. (1988)
Bird Stewart JA Genetic analysis of families of patients with Behçet’s syndrome: data incompatible with autosomal recessive mode of inheritance. Ann Rheum Dis. 45: 265–268. (1986).
Yazici H. Cicek B. Basaran G, Hamuryudan V, Cakir N, Dimitriatis I, Yurdakul S, Moral F, Ozyazgan Y, Mat C, Tuzun Y. Behçet’s syndrome with emphasis on clinical genetics and mortality. In The Vasculitides — Science and Practice (ed. Ansell, Bacon, Lee and Yazici), Chapman and Hall, London. 199–206. (1996).
Tuzun Y, Yazici H, Pazarli H, Yalcin B, Yurdakul S, Muftuoglu A. The usefulness of the nonspecific hypersensitivity (pathergy) test in Behçet’s disease in Turkey. Acta Dermatovener (Stockholm). 59: 77–79. (1979).
Cakir N, Yazici H, Chamberlain MA, Barnes CG, Akcasu A, Atasoy S. The response to monosdium urate (MSU) crystals in Behçet’s Syndrome. Ann Rheum Dis. 50: 634–636. (1991)
Yazici H, Chamberlain MA, Schreuder I, Bird Stewart J, Denman M. HLA B5 and Behçet’s disease. Ann Rheum Dis. 42: 602–603. (1983).
Fresko I, Soy M, Hamuryudan V, Yurdakul S, Yavuz S, Turner Z, Yazici H. Genetic Anticipation in Behçet’s syndrome. Ann Rheum Dis (in print).
Yazici H. The place of Behçet’s syndrome among the autoimmune diseases. Int Rev Immunol. 14(1): 1–10.
Eksioglu-Demiralp, personal communication.
Stanford MR, Kasp E, Whiston R, Hasan A, Todryk S, Shinnik T, Mizushima Y, Dumonde DC, van der Zee R, Lehner T. Heat shock protein peptides reactive in patients with Behçet’s disease are uveotigenic in Lewis rats. Clin Exp Immunol. 97: 226–231. (1994).
Hasan A, Fortune F, Wilson A, Warr K, Shinnik T, Mizushima Y, van de Zee Y, Stanford RS, Sanderson J, Lehner T. Role of γδ T cells in pathogenesis and diagnosis of Behçet’s disease. Lancet. 347: 789–794. (1996).
Lesprit P, Wechsler B, Piette JC, Du-Buotin LT, Godeau P, Alhenc-gelas Aiach M. Activated protein C resistance caused by factor V Arg 506→Gln mutation has no role in thrombotic manifestations of Behçet’s disease. Ann Rheum Dis. 54: 860. (1995).
Gul A, Ozbek U, Ozturk C, Inane M, Konice M, Ozcelik T. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet’s disease. Br J Rheumatol. 35: 1178–1180 (1996).
Gul A, Esin S, Dilsen N, Konice M, Wigzell H, Biberfield P. The immunology of the skin pathergy reaction in Behçet’s disease. Br J Dermatol. 35: 1178–1180 (1995).
Fresko I, Yazici H, Bayramicli M, Yurdakul S, Mat C. Effect of surgical cleaning of the skin on the pathergy phenomenon in Behçet’s syndrome. Ann Rheum Dis. 52: 619–620 (1993).
Takeno M, Kariyone A, Yamashita N, Takiguchi M, Mizushima Y, Kaneoka H, Sakane T. Excessive function of peripheral blood neutrophils from patients with Behçet’s disease and from HLZA-B51 transgenic mice. Arthritis Rheum. 38: 426–433 (1995).
Tuzun H, Besirli K, Sayin A, Vural FS, Hamuryudan V, Hizli N, Yurdakul S, Yazici H. Management of aneurysms in Behçet’s syndrome: an analysis of 24 patients. Surgery 12: 150–156. (1997).
Lee J, Lee CW, Song CH, Lee CH, Suh CH, Park YB, Lee WK, Lee SK. Postoperative recurrence in intestinal Behçet’s disease. Arthritis Rheum. 40 (suppl. 1): S66 (1997).
Mat C, Nazarbakhi M, Tuzun Y, Hamuryudan V, Hizli N, Yurdakul S, Ozyazgan Y, Yazici H. Wound healing in Behçet’s syndrome. Int J Dermatol (in print).
Yazici H, Tuzum Y, Tammam AB, Yurdakul S, Serdaroglu S, Pazarli H, Muftuoglu A. The male patients with Behçet’s syndrome have stronger pathergy reactions. Clin Exp Rheumatol. 3: 137–141. (1985).
Yazici H, Basaran G, Hamuryudan V, Hizli N, Yurdakul S, Mat C, Tuzun Y, Oyazgan Y, Dimitriyatis I. The ten-year mortality in Behçet’s syndrome. Br J Rheumatol. 35: 139–141 (1996).
Mat C, Demirkesen C, Cokerler (Arikan) O, Cetiner B, Fresko I, Yurdakul S, Tuzun Y, Yazici H. Androgen receptor density in scrotat skin of Behçet’s syndrome. In the Book of Abstracts of the Fourth Turkey-Korea Joint Meeting of Behçet s Disease. Kyongju, Korea. 1997.
Yazici H, Mat C, Deniz S, Iscimen A, Yurdakul S, Tuzun Y, Hekim N, Yazici Y. Sebum production is increased in Behçet’s syndrome and even more so in rheumatoid arthritis. Clin Exp Rheumatol 5: 371–374. (1987).
Jorizzo JL, Abernethy JL, White WL, Mangelsdorf HC, Zouboulis CC, Sarica R, Gaffney K, Mat C, Yazici H, al Dalaan A, Assaad-Khalil SH, Kaneko F. Mucocutaneous criteria for the diagnosis of Behçet’s disease: an analysis of clinicopathological data from multiple international centers. J Am Acad Dermatol. 32: 968–976(1995).
Ergun T, Gurbuz O, Dogusoy G, Mat C, Yazici H. Histopathological features of the pustular lesions of Behçet’s syndrome. Int J Dermatol (in print).
Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt G, Yazici B, Somai S, Muftuoglu A. A controlled trial of azathioprine in Behçet’s syndrome. N Eng J Med. 322: 281–285 (1990).
Hamuryudan V, Ozyazgan H, Hizli N, Mat C, Yurdakul S,. Tuzun Y, Senocak M, Yazici H. Azathioprine in Behçet’s syndrome. Arthritis Rheum 40: 769–774 (1997).
Hamuryudan V, Mat C, Saip S, Ozyagzan Y, Siva A, Yurdakul S, Zwingenberger K, Yazici H. Randomised and placebo controlled trial of two different doses of thalidomide in Behçet’s syndrome. Arthritis Rheum. 40(suppl 1): S65(1997).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Yazici, H. et al. (1999). Behçet’s Syndrome. In: Mallia, C., Uitto, J. (eds) Rheumaderm. Advances in Experimental Medicine and Biology, vol 455. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4857-7_19
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4857-7_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7203-5
Online ISBN: 978-1-4615-4857-7
eBook Packages: Springer Book Archive